Literature DB >> 28838709

Optimal Treatment of Stage IIIA-N2 Non-Small Cell Lung Cancer: A Neverending Story?

Paul E Van Schil1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28838709     DOI： 10.1016/j.jtho.2017.07.001

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  2 in total

1.  Radiotherapy Dose and Induction Chemotherapy Cycles Are Associated With Prognosis and Toxicity Risk: A Retrospective Study of 227 Patients With Unresectable Stage III Non-Small-Cell Lung Cancer.

Authors:  Liyao Chen; Yu Hou; Yaoxiong Xia; Li Chang; Xianmin Diao; Li Wang; Lan Li; Qing Long; Ying Liu; Yan Liu; Wenhui Li
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

2.  Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.

Authors:  S Senan; M Özgüroğlu; D Daniel; A Villegas; D Vicente; S Murakami; R Hui; C Faivre-Finn; L Paz-Ares; Y L Wu; H Mann; P A Dennis; S J Antonia
Journal:  ESMO Open       Date:  2022-03-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.